# Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

> **NCT02582684** · PHASE2 · COMPLETED · sponsor: **Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections** · enrollment: 122 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Dolutegravir
- **DRUG:** Lamivudine

## Key facts

- **NCT ID:** NCT02582684
- **Lead sponsor:** Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-08
- **Primary completion:** 2017-02-28
- **Final completion:** 2017-09-26
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2018-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02582684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02582684, "Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02582684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*